
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
Ezetimibe (Zetia) is an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total cholesterol.
Medication Pearl of the Day: Ezetimibe (Zetia)
Indication: Ezetimibe (Zetia) is an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, Apo B, and non-high-density lipoprotein cholesterol in patients with primary hyperlipidemia, alone or in combination with an HMGCoA reductase inhibitor (statin).
Insight:
Source:





